PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.
|Number of pages||7|
|Publication status||Published - 01-07-2016|
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging